Clinical Trial Update: Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 [Phase 1]

View source ↗

Summary

Phase I trial evaluating intratumoral GRm13Z40-2 T-cell therapy (genetically modified allogeneic CD8+ T cells expressing IL-13-Zetakine and HyTK, glucocorticoid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Ependymoma
• Anaplastic Oligodendroglioma
• Brainstem Glioma
• Ependymoblastoma
• Glioblastoma
• Gliosarcoma
• Pineal Gland Astrocytoma

Drugs mentioned

• GRm13Z40-2 T-cell therapy (GRm13Z40-2 allogeneic CD8+ cytolytic T-cell line expressing IL-13-Zetakine and HyTK; glucocorticoid resistant)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Status: COMPLETED